Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
G1 Therapeutics (GTHX) Investor Presentation - Slideshow
06:10pm, Thursday, 13'th Aug 2020
The following slide deck was published by G1 Therapeutics, Inc. in conjunction with this event..
G1 Therapeutics Provides Second Quarter 2020 Corporate and Financial Update
08:01pm, Wednesday, 05'th Aug 2020
\- Submitted New Drug Application (NDA) for trilaciclib in small cell lung cancer (SCLC) \- Co-promotion agreement with Boehringer Ingelheim for U.S. trilaciclib launch \- Partnership for trilacicli
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
12:00am, Wednesday, 05'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August 2020
11:00am, Tuesday, 04'th Aug 2020
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D.
G1 Therapeutics and Simcere Announce Exclusive License Agreement for Trilaciclib in Greater China
11:00am, Monday, 03'rd Aug 2020
* Simcere to lead clinical development, regulatory submissions and commercialization of trilaciclib across all indications in Greater China * G1 to receive $14 million upfront payment, sales roya
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020
11:01am, Wednesday, 29'th Jul 2020
RESEARCH TRIANGLE PARK, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results
12:25pm, Thursday, 23'rd Jul 2020
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) * ABIOMED, Inc. (NASDAQ: ABMD) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Bio-Rad Laboratories, Inc. Class B Co
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results
12:00am, Thursday, 23'rd Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 22)
ABIOMED, Inc. (NASDAQ: ABMD)
Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO)
Bio-Rad Laboratories,...
G1 Therapeutics Announces License Agreement for Lerociclib
10:00pm, Wednesday, 22'nd Jul 2020
\- G1 to receive $20 million upfront payment, sales royalties and potential milestone payments of up to $290 million for commercialization of lerociclib in the U.S., Europe, Japan RESEARCH TRIANGLE P
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
10:13am, Wednesday, 01'st Jul 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on G1 Therapeutics
Were Hedge Funds Right About Betting On G1 Therapeutics, Inc. (GTHX)?
08:36pm, Tuesday, 30'th Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin
G1 Therapeutics, Inc. (Nasdaq: GTHX) and Boehringer Ingelheim today announced that the companies have entered into a co-promotion agreement for trilaciclib in the United States and Puerto Rico. Under
Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
11:34am, Sunday, 28'th Jun 2020
VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company
G1 Therapeutics Has Multiple Roadmaps To A Multi-Billion Dollar Market Cap
06:04pm, Wednesday, 24'th Jun 2020
GTHX should submit an NDA for its Trilaciclib that, if approved, could generate $500MM-$1Billion in revenues/year in small-cell lung cancer (69,000 patients wor
